Harbour Investments Inc. Has $396,000 Holdings in Viking Therapeutics, Inc. $VKTX

Harbour Investments Inc. raised its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,961 shares of the biotechnology company’s stock after buying an additional 326 shares during the quarter. Harbour Investments Inc.’s holdings in Viking Therapeutics were worth $396,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its stake in Viking Therapeutics by 121.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company’s stock valued at $718,000 after buying an additional 16,302 shares during the period. Wealth Management Associates Inc. acquired a new position in shares of Viking Therapeutics during the first quarter worth approximately $241,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Viking Therapeutics during the second quarter worth approximately $1,367,000. U.S. Capital Wealth Advisors LLC raised its position in shares of Viking Therapeutics by 77.7% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 63,546 shares of the biotechnology company’s stock worth $1,684,000 after purchasing an additional 27,795 shares during the period. Finally, Wesbanco Bank Inc. raised its position in shares of Viking Therapeutics by 118.5% during the second quarter. Wesbanco Bank Inc. now owns 52,000 shares of the biotechnology company’s stock worth $1,378,000 after purchasing an additional 28,200 shares during the period. 76.03% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

VKTX has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Monday, September 29th. Citigroup upped their target price on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Raymond James Financial lowered their target price on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating on the stock in a research report on Thursday, July 24th. BTIG Research reaffirmed a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a research report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.42.

Viking Therapeutics Trading Up 0.7%

NASDAQ VKTX opened at $33.75 on Tuesday. The firm has a market capitalization of $3.79 billion, a P/E ratio of -22.06 and a beta of 0.64. The business has a fifty day simple moving average of $29.14 and a 200 day simple moving average of $28.49. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.73.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). Viking Therapeutics’s revenue was up NaN% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.20) earnings per share. As a group, sell-side analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.